12/4
07:30 am
pstv
Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting
High
Report
Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting
12/1
01:49 pm
pstv
Plus Therapeutics (NASDAQ:PSTV) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.
Medium
Report
Plus Therapeutics (NASDAQ:PSTV) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.
12/1
07:30 am
pstv
Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Study Results for Leptomeningeal Metastases at the 2025 San Antonio Breast Cancer Symposium
Medium
Report
Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Study Results for Leptomeningeal Metastases at the 2025 San Antonio Breast Cancer Symposium
11/26
10:59 am
pstv
Plus Therapeutics (NASDAQ:PSTV) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Plus Therapeutics (NASDAQ:PSTV) had its "buy" rating reaffirmed by analysts at HC Wainwright.
11/24
07:30 am
pstv
Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ™ in Leptomeningeal Metastases
Medium
Report
Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ™ in Leptomeningeal Metastases
11/21
08:05 am
pstv
Plus Therapeutics (NASDAQ:PSTV) had its price target lowered by analysts at Ascendiant Capital Markets from $21.00 to $19.00. They now have a "buy" rating on the stock.
Medium
Report
Plus Therapeutics (NASDAQ:PSTV) had its price target lowered by analysts at Ascendiant Capital Markets from $21.00 to $19.00. They now have a "buy" rating on the stock.
11/20
09:46 am
pstv
Plus Therapeutics (NASDAQ:PSTV) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.
Medium
Report
Plus Therapeutics (NASDAQ:PSTV) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.
11/20
07:42 am
pstv
Plus Therapeutics Secures National Coverage Agreement with Humana for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer [Yahoo! Finance]
High
Report
Plus Therapeutics Secures National Coverage Agreement with Humana for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer [Yahoo! Finance]
11/20
07:30 am
pstv
Plus Therapeutics Secures National Coverage Agreement with Humana for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
Medium
Report
Plus Therapeutics Secures National Coverage Agreement with Humana for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
11/17
07:42 am
pstv
Plus Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement [Yahoo! Finance]
High
Report
Plus Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement [Yahoo! Finance]
11/17
07:30 am
pstv
Plus Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement
Medium
Report
Plus Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement
11/13
07:22 am
pstv
Plus Therapeutics (NASDAQ:PSTV) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Medium
Report
Plus Therapeutics (NASDAQ:PSTV) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
11/6
07:30 am
pstv
Plus Therapeutics Highlights ReSPECT-LM Clinical Trial Results at 40th SITC Annual Meeting, Melanoma Research Foundation Brain Metastases Summit 4.0
Medium
Report
Plus Therapeutics Highlights ReSPECT-LM Clinical Trial Results at 40th SITC Annual Meeting, Melanoma Research Foundation Brain Metastases Summit 4.0
11/3
08:03 am
pstv
Plus Therapeutics (NASDAQ:PSTV) had its price target lowered by analysts at HC Wainwright from $3.00 to $2.00. They now have a "buy" rating on the stock.
Low
Report
Plus Therapeutics (NASDAQ:PSTV) had its price target lowered by analysts at HC Wainwright from $3.00 to $2.00. They now have a "buy" rating on the stock.
10/31
08:06 am
pstv
Plus Therapeutics (NASDAQ:PSTV) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.
Medium
Report
Plus Therapeutics (NASDAQ:PSTV) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.
10/30
08:12 pm
pstv
Plus Therapeutics Reports Third Quarter Financial Results and Recent Business Highlights [Yahoo! Finance]
Low
Report
Plus Therapeutics Reports Third Quarter Financial Results and Recent Business Highlights [Yahoo! Finance]
10/30
04:15 pm
pstv
Plus Therapeutics Reports Third Quarter Financial Results and Recent Business Highlights
Low
Report
Plus Therapeutics Reports Third Quarter Financial Results and Recent Business Highlights
10/21
08:45 am
pstv
Plus Therapeutics (NASDAQ:PSTV) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.
Medium
Report
Plus Therapeutics (NASDAQ:PSTV) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.
10/21
07:30 am
pstv
Plus Therapeutics Updates on CNSide® Diagnostic Platform Launch
Medium
Report
Plus Therapeutics Updates on CNSide® Diagnostic Platform Launch
10/15
07:11 am
pstv
Plus Therapeutics (NASDAQ:PSTV) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Medium
Report
Plus Therapeutics (NASDAQ:PSTV) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
10/6
08:09 am
pstv
Plus Therapeutics (NASDAQ:PSTV) had its price target raised by analysts at Ascendiant Capital Markets from $20.50 to $21.00. They now have a "buy" rating on the stock.
High
Report
Plus Therapeutics (NASDAQ:PSTV) had its price target raised by analysts at Ascendiant Capital Markets from $20.50 to $21.00. They now have a "buy" rating on the stock.
9/25
10:39 am
pstv
BC-Most Active Stocks [Yahoo! Finance]
Low
Report
BC-Most Active Stocks [Yahoo! Finance]
9/25
08:22 am
pstv
Plus Therapeutics (NASDAQ:PSTV) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.
Medium
Report
Plus Therapeutics (NASDAQ:PSTV) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.
9/25
08:10 am
pstv
Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer [Yahoo! Finance]
Medium
Report
Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer [Yahoo! Finance]
9/25
07:30 am
pstv
Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
High
Report
Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer